« Previous Next » Leukemia Research
Volume 26, Issue 10 , Pages 965-966 , October 2002

Thalidomide in the treatment of myelodysplastic syndrome with fibrosis

Panagiotis Tsirigotis
- Third Department of Internal Medicine, First Hospital of Athens, Social Insurance Foundation, Zaimi street-Melissia, 15127 Athens, Greece
- Corresponding author. Tel.: +30-1-8042320; fax: +30-1-8041837
Evangelos Venetis
- Third Department of Internal Medicine, First Hospital of Athens, Social Insurance Foundation, Zaimi street-Melissia, 15127 Athens, Greece
Dimitra Rontogianni
- Histopathology Department, Evangelismos Hospital, 15127 Athens, Greece
John Dervenoulas
- Second Department of Internal Medicine, Evangelismos Hospital, 15127 Athens, Greece
Flora Kontopidou
- Third Department of Internal Medicine, First Hospital of Athens, Social Insurance Foundation, Zaimi street-Melissia, 15127 Athens, Greece
Panos Apostolidis
- Third Department of Internal Medicine, First Hospital of Athens, Social Insurance Foundation, Zaimi street-Melissia, 15127 Athens, Greece

Received 7 November 2001 ,Accepted 5 February 2002.

References

Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindeberg E. A patient oriented approach to treatment of myelodysplastic syndromes. Haematologica. 1998;83:910–935
- MEDLINE
Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndromes: outcome analysis according to IPSS score. Leukemia 1998;12 (Suppl 1):25–9.
Munshi NC, Desikan KR, Barlogie B. Clinical experience with thalidomide in multiple myeloma: phase II trial results in refractory disease and ongoing studies. Semin. Hematol. 2000;37(Suppl. 3):15–21
Calderon P, Anzilotti M, Phelps R. Thalidomide in dermatology: new indications for an old drug. Int. J. Dermatol. 1997;36:881–887
- MEDLINE
Stirling DI. Pharmacology of thalidomide. Semin. Hematol. 2000;37(Suppl 3):5–14